Concepedia

T. Henderson

TH

Statistics

Publications

4

Citations

604

H-Index

4

Active since

2003

Affiliations

Vanderbilt-Ingram Cancer Center(Current)

The University of Texas MD Anderson Cancer Center

T. Henderson is an author at Vanderbilt-Ingram Cancer Center specializing in lung cancer pharmacotherapy, molecular oncology, and pharmacology.

Publications per year

2003–2005

4

Publications

4

Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer

Roy S. Herbst, David H. Johnson, Eric D. Mininberg et al. · Journal of Clinical Oncology · 2005 · 536 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase I/II trial evaluating the anti-VEGF MAb bevacizumab in combination with erlotinib, a HER1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer

Alan B. Sandler, George R. Blumenschein, T. Henderson et al. · Journal of Clinical Oncology · 2004 · 38 citations

Medicine, Oncology, Pharmacology +16

977 Phase I/II trial evaluating blockade of tumour blood supply and tumour cell proliferation with combined bevacizumab and erlotinib HCl as targeted cancer therapy in patients with recurrent non-small cell lung cancer

Roy S. Herbst, Eric D. Mininberg, T. Henderson et al. · European Journal of Cancer Supplements · 2003 · 17 citations

Medicine, Oncology, Pharmacology +14

Phase I/II trial of bevacizumab plus erlotinib for patients with recurrent non-small cell lung cancer: Correlation of treatment response with mutations of the EGFR tyrosine kinase gene

Anne S. Tsao, Roy S. Herbst, Alan Sandler et al. · Journal of Clinical Oncology · 2005 · 13 citations

Medicine, Oncology, Pharmacology +16

1–4 of 4